TrademarkDir
METAVALENT
DEAD

Serial Number

76244626

Owner

Advanced Medicine, Inc.

Attorney

PAUL E. FAHRENKOPF

Filing Date

Apr 23, 2001

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

METAVALENT Trademark

Serial Number: 76244626

METAVALENT is a trademark filed by Advanced Medicine, Inc. on April 23, 2001. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Advanced Medicine, Inc. (19 trademarks)

280 Utah Avenue
South San Francisco, CA 94080

Entity Type: 03

THERAVANCE, INC. (34 trademarks)

901 GATEWAY BLVD
SOUTH SAN FRANCISCO, CA 94080

Entity Type: 03

Trademark Details

Filing Date

April 23, 2001

Registration Date

Not Registered

Published for Opposition

September 11, 2001

Goods & Services

full line of pharmaceuticals

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Mar 3, 2005 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Mar 3, 2005 ABN6
SOU EXTENSION 5 GRANTED
May 5, 2004 EX5G
CASE FILE IN TICRS
May 3, 2004 CFIT
SOU EXTENSION 5 FILED
Apr 23, 2004 EXT5
SOU TEAS EXTENSION RECEIVED
Apr 23, 2004 EEXT
SOU EXTENSION 4 GRANTED
Jun 13, 2003 EX4G
SOU EXTENSION 4 FILED
Jun 10, 2003 EXT4
SOU TEAS EXTENSION RECEIVED
Jun 9, 2003 EEXT
SOU EXTENSION 3 GRANTED
Jun 5, 2003 EX3G
SOU EXTENSION 3 FILED
Jun 2, 2003 EXT3
SOU TEAS EXTENSION RECEIVED
May 30, 2003 EEXT
SOU EXTENSION 2 GRANTED
Feb 8, 2003 EX2G
PAPER RECEIVED
Dec 11, 2002 MAIL
SOU EXTENSION 2 FILED
Nov 26, 2002 EXT2
PAPER RECEIVED
Nov 26, 2002 MAIL
SOU EXTENSION 1 GRANTED
Feb 16, 2002 EX1G
SOU EXTENSION 1 FILED
Jan 29, 2002 EXT1
NOA MAILED - SOU REQUIRED FROM APPLICANT
Dec 4, 2001 NOAM
PUBLISHED FOR OPPOSITION
Sep 11, 2001 PUBO
NOTICE OF PUBLICATION
Aug 22, 2001 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 26, 2001 CNSA
ASSIGNED TO EXAMINER
Jul 26, 2001 DOCK

Related Trademarks

More from this Owner

INNOVIVA

INNOVIVA

INNOVIVA

INNOVIVA

INNOVIVA

INNOVIVA

INNOVIVA

INNOVIVA

INNOVIVA

INNOVIVA

INVEST IN THE FUTURE OF BREATH

INVEST IN THE FUTURE OF BREATH